, and HILDEN,
September 13, 2012
- QIAGEN's cutting-edge ESEQuant Lateral Flow System will run Lepu Medical's tests for key cardiac biomarkers to deliver lifesaving information in emergency rooms
- Cardiac testing adds further momentum for QIAGEN in fast-growing Chinese market
- Pioneering ESEQuant platform achieves first regulatory approval in human healthcare, expanding QIAGEN's global Point of Need business
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced an agreement with Lepu Medical Technology (
) Co., Ltd., a leading medical device company in
, to provide QIAGEN's ESEQuant Lateral Flow System for use in emergency rooms with Lepu's tests for cardiac markers that diagnose acute myocardial infarction (heart attack). The agreement expands QIAGEN's presence in
and adds a new point of need diagnostics application.
State Food and Drug Administration (SFDA) has approved the ESEQuant Lateral Flow detection system with Lepu Medical's five cardiac marker tests. Lepu will market the system in
under the name LEPU Quant-Gold. Globally, this is the first regulatory approval in human healthcare for QIAGEN's pioneering ESEQuant platform which was acquired in 2010.
"We are very pleased to begin this relationship with the Lepu Group and meet a pressing need for heart patients by combining ESEQuant's quick turnaround time with the reliability of Lepu's tests for cardiac biomarkers," said Dr.
, Head of Global Strategic Alliances & OEM at QIAGEN. "This agreement advances two strategic initiatives: First, our geographic presence is further broadened by the addition of important point of need assays in
today represents QIAGEN's third-largest country in sales. Secondly, we are driving platform success by launching ESEQuant as an SFDA-approved device in a lifesaving medical application, a milestone for our emerging Point of Need portfolio."
QIAGEN's Point of Need portfolio is rapidly expanding. The growth is based on the benefits of the revolutionary ESE platform portfolio as well as on the value of the pipeline and portfolio of molecular and other assays for these platforms. Earlier in 2012 QIAGEN acquired the AmniSure immunoassay for rupture of amniotic membranes in pregnant women, a self-contained test used in doctor's offices and maternity units, and joined a global initiative with the Bill and Melinda Gates Foundation to create much-needed platforms for point of care diagnosis in the developing world. "Our vision for point of need is to bring the speed and reliability of advanced diagnostics into emergency rooms, physician offices and other places where care is given without immediate access to laboratories", Dr. Krieg-Schneider added.